due to a change in probability of performance conditions for certain executives' share awards. The year ended December 31, 2024 includes reversals of stock compensation expense previously recognized ...

HOUSTON, July 23, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") reported second quarter 2025 revenue of $130,200,000. Core's operating income was $15 ...

(1) Three months ended September 30, 2024 includes reversals of stock compensation expense previously recognized due to a change in probability of performance condition for certain executive's share ...

HOUSTON, Feb. 4, 2026 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core," "Core Lab," or the "Company") reported fourth quarter 2025 revenue of $138,300,000. Core's operating income was ...

HOUSTON, May 7, 2025 /PRNewswire/ -- Core Laboratories Inc. (NYSE: "CLB") ("Core", "Core Lab", or the "Company") is pleased to announce the opening of its new Unconventional Core Analysis Laboratory ...

Ariel Investments, an investment management company, released its “Ariel Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund delivered a +3.22% return in ...

Earnings call Core Laboratories reported Q4 2025 revenue of $138.3M, up 3% sequentially and 7% YoY, with strong international service demand offsetting US softness. EPS ex items was $0.21, flat YoY.

FOURTH QUARTER REVENUE OF $138.3 MILLION, UP 3% SEQUENTIALLY AND UP 7% YEAR-OVER-YEAR FOURTH QUARTER OPERATING INCOME OF $15.8 MILLION; EX-ITEMS, $15.7 MILLION, DOWN 5% SEQUENTIALLY AND FLAT YEAR-OVER ...

Wide-moat Core Laboratories posted third-quarter results mostly in line with our estimates. Revenue of $134 million was up 3% sequentially and 7% year over year, while operating income of $20 million ...